Pinocembrin

Drug Profile

Pinocembrin

Alternative Names: 5,7-Dihydroxyflavanone; DL-0108

Latest Information Update: 28 Jun 2016

Price : $50

At a glance

  • Originator CSPC ZhongQi Pharmaceutical Technology
  • Class Anti-ischaemics; Flavanones; Flavonoids; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Stroke

Most Recent Events

  • 16 Jun 2016 CSPC suspends a phase II trial in Stroke in China (NCT02059785)
  • 01 Jun 2013 Phase-II clinical trials in Stroke in China (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top